Novartis AG (LSE:0HKE)
£ 3657.04 0 (0%) Market Cap: 60.95 Bil Enterprise Value: 74.78 Bil PE Ratio: 14.34 PB Ratio: 5.34 GF Score: 77/100

Novartis AG to Discuss Entresto® FDA Label Expansion Investor Q&A Call Transcript

Feb 17, 2021 / 01:00PM GMT
Operator

Good morning, and good afternoon, and welcome to the Novartis Investor Conference Call on Entresto FDA Label Expansion. (Operator Instructions) The conference is being recorded. (Operator Instructions) A recording of the conference call, including the Q&A session will be available on our website shortly after the call ends. (Operator Instructions)

With that, I would like to hand over to Mr. Samir Shah, Head of Investor Relations. Please go ahead, sir.

Samir Shah
Novartis AG - Global Head of IR

Thank you very much, and good morning, and good afternoon to everybody. Big thank you for taking the time to participate in this -- mainly Q&A session or investor call in relation to the Entresto label update.

With us today, we have David Soergel MD, who's the Global Head of the Cardiovascular, Renal and Metabolism Development unit. We also have Rod Wooten, who is the Global Head for Marketing at Novartis Pharmaceuticals. I think many of you will be familiar with both these people who was present at the Novartis management meeting back in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot